MLN 8237: all 60 studies that test it

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast CancerNot yet recruitingNCT07706179Phase 2
• A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)RecruitingNCT07465757Phase 2
• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerRecruitingNCT06369285Phase 2
• A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerRecruitingNCT06095505Phase 2
• Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell CancerCompletedNCT04555837Phase 1/2Results posted
• Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast CancerCompletedNCT02719691Phase 1Results posted
• Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AMLCompletedNCT02560025Phase 2Results posted
• Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic LeukemiaStatus unknownNCT02530619Not applicableResults posted
• Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid TumorsTerminatedNCT02367352Phase 1Results posted
• A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic MalignanciesCompletedNCT02327169Phase 1Results posted
• Phase II Trial of Alisertib (MLN8237) in Salvage Malignant MesotheliomaCompletedNCT02293005Phase 2Results posted
• A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory LymphomaCompletedNCT02259010Phase 1Results posted
• Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic FunctionCompletedNCT02214147Phase 1Results posted
• Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast CancerCompletedNCT02187991Phase 2Results posted
• Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade GliomasCompletedNCT02186509Phase 1Results posted
• Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)CompletedNCT02038647Phase 2Results posted
• Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or LymphomasCompletedNCT01898078Phase 1Results posted
• Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate CancerCompletedNCT01848067Phase 1/2Results posted
• Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of AlisertibCompletedNCT01844583Phase 1Results posted
• Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT01812005Phase 2Results posted
• A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate CancerCompletedNCT01799278Phase 2Results posted
• Mass Balance, Pharmacokinetics and Metabolism Study of AlisertibCompletedNCT01714947Phase 1Results posted
• Alisertib in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01653028Phase 2Results posted
• Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the UterusCompletedNCT01637961Phase 2Results posted
• Study of MLN8237 in Combination With Irinotecan and TemozolomideCompletedNCT01601535Phase 1/2Results posted
• A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or LymphomasCompletedNCT01512758Phase 1Results posted
• Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell LymphomaCompletedNCT01482962Phase 3Results posted
• Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin LymphomaCompletedNCT01466881Phase 2Results posted
• Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01154816Phase 2Results posted
• A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel RegimenCompletedNCT01094288Phase 1Results posted
• Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast CancerCompletedNCT01091428Phase 2Results posted
• Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal MalignanciesCompletedNCT01045421Phase 1/2Results posted
• Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01034553Phase 1/2Results posted
• Study of MLN8237 in Participants With Advanced Solid TumorsCompletedNCT00962091Phase 1Results posted
• MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal CarcinomaCompletedNCT00853307Phase 2Results posted
• A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic SyndromeCompletedNCT00830518Phase 2Results posted
• Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's LymphomaCompletedNCT00807495Phase 2Results posted
• Study of MLN8237 in Participants With Advanced Hematological MalignanciesCompletedNCT00697346Phase 1Results posted
• A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced MalignanciesCompletedNCT00651664Phase 1Results posted
• A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid TumorsCompletedNCT00500903Phase 1Results posted
• Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung CancerCompletedNCT04479306Phase 1
• Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung CancerCompletedNCT04085315Phase 1
• Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated MalignanciesWithdrawnNCT02812056Phase 1
• Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid MalignanciesWithdrawnNCT02780011Phase 1
• A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell LymphomasTerminatedNCT02700022Phase 1
• MLN8237 to Treat Children With Relapsed/Refractory Solid TumorsCompletedNCT02444884Phase 1
• Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal TumorsCompletedNCT02319018Phase 1
• Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by SurgeryCompletedNCT02219789Phase 1
• Alisertib in Chemotherapy-pretreated Urothelial CancerCompletedNCT02109328Phase 2
• Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic CancerCompletedNCT01924260Phase 1
• Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal CancerCompletedNCT01923337Phase 1
• Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell LymphomasCompletedNCT01897012Phase 1
• Alisertib for Acute Myeloid LeukemiaCompletedNCT01779843Phase 1
• Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin LymphomaActive, not recruitingNCT01695941Phase 1
• Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid MalignanciesCompletedNCT01677559Phase 1
• Phase I Study of MLN8237 and Pazopanib in Patients With Solid TumorsCompletedNCT01639911Phase 1
• Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic MalignanciesWithdrawnNCT01613261Phase 1
• Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaCompletedNCT01567709Phase 1
• MLN8237 in Head and Neck CancerCompletedNCT01540682Phase 1
• Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung CancerTerminatedNCT01471964Phase 1/2

← MLN 8237 overview